CSL (ASX:CSL; USOTC:CSLLY), a global biotechnology company, announced on Sunday the top-line outcome from its Phase three AEGIS-II trial assessing the efficacy and safety of CSL112 (apolipoprotein A-I [human]) compared to placebo in decreasing the risk of major adverse cardiovascular events (MACE) in subjects subsequent to an acute myocardial infarction (AMI).
The study has not met its primary efficacy endpoint of MACE decrease at 90 days. Due to this, there are no plans for a near-term regulatory filing. The study did not identify any major safety or tolerability concerns with the product. Further evaluation of AEGIS-II is ongoing and primary outcome will be showcased at the American College of Cardiology Scientific Sessions, scheduled at 6 April 2024, and published in a peer-reviewed journal.
The AEGIS-II trial enrolled more than 18,200 subjects from more than 850 sites in 49 countries. Subjects were randomised to receive four weekly doses of the product or placebo started within five days of first medical contact.
Indivior updates on Aelis Farma's Phase 2B study of AEF0117 for Cannabis Use Disorder
Vesper Bio announces positive Phase I results for FTD treatment
Empower Pharmacy names new president
Innovent's IBI363 receives US FDA Fast Track Designation
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Medicilon USA begins operations at second R&D centre in Massachusetts
CS Genetics names new chief operating officer and chief scientific officer
Expanse Medical names new chief executive officer and FlowPhysix board member